Abstract
The development of Imatinib has clearly created a new paradigm for the treatment of soft tissue sarcomas. Although long term follow-up data are yet lacking it is already quite evident the drug is nothing less than a break-through in the treatment of GIST. It will be of crucial importance in the next coming years to establish a functional relationship between presence of a target for treatment and its involvement in actual tumor growth. For KIT this was evident in GIST and this is likely one of the reason for the success. And other development of signal transduction inhibitors may have failed due to the lack of such information.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
